NEW YORK (AP) — U.S. stocks rose Monday, led by those seen as benefiting the most from Donald Trump’s reelection as president, but drops for some high-profile Big Tech stocks kept indexes in ...

Learn More Some rock-solid dividend stocks took a beating after the election, and that could mean opportunity. The stock market as a whole rocketed higher after the results of the election were ...

US stocks closed mixed on Wednesday as investors weighed fresh consumer inflation data that looked to keep the Federal Reserve on pace for another rate cut next month. Meanwhile, bitcoin (BTC-USD ...

We model a revenue/PAT CAGR of 26%/31% over FY2024-FY2027E. We reiterate BUY with a PT of Rs. 870 (46x on FY27 EPS of Rs 18.9).

Chardan Capital Maintains Buy on Cognition Therapeutics, Maintains $11 Price Target Analyst ratings measure the expected performance of a stock during a given time period. Analysts and brokerage ...

The right online broker can help you execute your investment strategy and make trading cheap stocks seamless. Take a look at some of Benzinga’s favorites. You have found stocks to buy now cheap ...

Stocks ended higher Monday, with the Dow, S&P 500 and Nasdaq Composite building on last week's record run. The Dow closed above 44,000 for the first time, while the S&P 500 ended just above the ...

The highlight of the week was the US$1 billion accord announced on the final day of the 2024 FII summit by the Saudi sovereign wealth fund and the HKMA.

Here’s one reason investors should stick with stocks — despite warnings of a ‘lost decade’ ahead. U.S. stocks finished mostly higher on Wednesday, with the S&P 500 barely eking out a gain ...

Stocks and bonds are two of the most traded types of assets—each available for sale on several different platforms or through a variety of markets or brokers. And there are important ...

Brookfield Infrastructure Corp. has a somewhat complicated corporate structure, but the stock offers an attractive combination of stability, dividend yield and growth. Annual dividend growth rate ...

The stock has more than doubled in 2024 but is still trading under $5. Investors are growing increasingly optimistic that imetelstat could gain additional approvals. Geron is in phase 3 clinical ...